Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

FDA clears Ibex Prostate Detect

June 2025—Ibex Medical Analytics has received FDA 510(k) clearance for Ibex Prostate Detect, an in vitro diagnostic, software only medical device that analyzes scanned histopathology whole slide images from prostate core needle biopsies prepared from H&E-stained formalin-fixed, paraffin-embedded tissue. If tissue suspicious for prostate cancer is identified, the system provides case- and slide-level alerts and includes an AI-generated heat map that identifies small and rare missed prostatic cancers.

FDA clears Beckman Coulter DxC 500i analyzer

June 2025—Beckman Coulter Diagnostics announced that its DxC 500i clinical analyzer received FDA 510(k) clearance. The integrated chemistry and immunoassay analyzer has a throughput of up to 800 clinical chemistry tests and 100 immunoassay tests per hour and features FlexMode operations, which prioritize immunoassay and chemistry testing according to each sample’s urgency.

Dr. Jonathan Epstein joins Advanced Uropathology

June 2025—Advanced Uropathology, a division of Integrated Medical Professionals, announced that urologic pathologist Jonathan Epstein, MD, has joined its team. Physicians, hospitals, and laboratories can now refer specimens directly to Dr. Epstein, who will provide second opinions and expert interpretations of complex urologic pathology cases.

MMQCI releases FilmArray tropical fever quality control

June 2025—Maine Molecular Quality Controls announced the release of the Film­Array TF control panel, for users of the FDA-cleared BioFire FilmArray tropical fever panel. The multiplexed control is intended for use as an external positive and negative assayed quality control to monitor the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of viral, bacterial, and parasitic pathogens. The kit includes six 200-μL positive controls and six 200-μL negative controls.

Labcorp acquires assets of NMHS ambulatory outreach lab business

June 2025—Labcorp and North Mississippi Health Services announced that Labcorp has completed its acquisition of North Mississippi Health Services’ ambulatory outreach laboratory business and is now a referral laboratory for NMHS’ seven hospitals and clinic laboratories. In addition, Labcorp will open three patient service centers in Tupelo, West Point, and Amory by midyear to increase availability of laboratory services in North Mississippi.

FDA clears Liaison Plex Gram-negative blood culture assay

June 2025—Diasorin announced it has received FDA 510(k) clearance for the Liaison Plex Gram-negative blood culture assay, the second of the company’s three multiplex molecular panels for blood culture pathogen identification on the Liaison Plex. The assay is designed to identify 27 targets—19 Gram-negative bacteria and eight relevant resistance gene targets, including Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Acinetobacter species, Citrobacter species, Enterobacter species, and Proteus species. Results are available about two hours after a Gram stain.

Visby gets clearance, CLIA waiver for POC respiratory test

June 2025—Visby Medical announced it has received 510(k) clearance and was granted a CLIA waiver from the FDA for its point-of-care Medical Respiratory Health test. The PCR test detects and differentiates between upper respiratory infections caused by influenza A and B and SARS-CoV-2 and provides results in less than 30 minutes.

Mayo Clinic, Kyan collaborate to expand access to cancer testing

June 2025—Mayo Clinic Laboratories and Kyan Technologies announced a collaboration to validate and provide Kyan’s Optim.AI across the United States. Optim.AI is an ex vivo drug sensitivity platform that combines small data AI and biological experiments. It provides insights into therapies for cancer patients and delivers efficiencies for cancer drug development. Mayo Clinic Labs will provide testing for physicians and researchers to support clinical and research decision-making for better treatment options.

Thermo Fisher launches centrifuges with GreenCool technology

June 2025—Thermo Fisher Scientific introduced new lines of floor-model centrifuges that feature natural refrigerant cooling systems compliant with European Union and U.S. Environmental Protection Agency fluorinated gas regulations. The Thermo Scientific Cryofuge, Bios, and Lynx centrifuges feature the company’s GreenCool technology, a next-generation natural refrigerant cooling system with a global warming potential of 1. Each model provides a reduction in energy consumption of up to 15 percent when compared with previous models.

StatLab adds new U.S. manufacturing capabilities

June 2025—StatLab Medical Products announced that it is vertically integrating the production of containers and lids at its facility in Arlington, Tex., where the company currently produces nearly 100 million prefills annually, and will begin blow-molding gallon bottles in Q2. StatLab says it will also absorb any tariff-related fees associated with products manufactured in its European facilities when selling directly to U.S. laboratories. These products include PiSmart cassette and slide printers, KT microscope slides, and KT coverglass.

MARKETPLACE

TRENDING